Pathophysiology of Low Fibrinogen in Acute Leukemia
Low fibrinogen in acute leukemia results from a complex coagulopathy involving consumptive coagulation combined with primary and secondary fibrinolysis, particularly severe in acute promyelocytic leukemia (APL). 1
Primary Mechanisms
The pathophysiology operates through multiple interconnected pathways:
Disseminated Intravascular Coagulation (DIC)
The dominant mechanism is DIC-mediated consumption of fibrinogen through excessive thrombin generation. 2 In acute myeloid leukemia (AML), 91% of patients demonstrate elevated thrombin-antithrombin III complex (TAT) levels, indicating widespread coagulation activation 3. This consumptive process depletes fibrinogen faster than the liver can synthesize it, particularly when combined with hyperfibrinolysis (elevated D-dimer levels found in 91% of AML patients) 3.
The correlation between TAT and fibrinogen levels is strongly negative (r = -0.57, P < 0.005), while TAT correlates positively with D-dimer (r = 0.89, P < 0.0005), confirming that thrombin generation drives both fibrinogen consumption and secondary fibrinolysis 3.
Hyperfibrinolysis
Secondary hyperfibrinolysis compounds fibrinogen depletion, with alpha-2-plasmin inhibitor deficiency allowing unopposed plasmin activity. 3, 4 The strong negative correlation between D-dimer and alpha-2-plasmin inhibitor (r = -0.77, P < 0.0005) demonstrates that as fibrinolysis intensifies, natural inhibitors become depleted 3.
In APL specifically, fibrinogenolysis (direct plasmin degradation of fibrinogen rather than fibrin) occurs when alpha-2-plasmin inhibitor falls below 60% of normal 4. This produces early fibrinogen degradation products with low anticoagulant activity, distinguishing it from typical plasmin-mediated fibrin breakdown.
Leukocyte Protease Activity
A third mechanism involves direct fibrinogen degradation by leukocyte-derived proteases, particularly elastase released from leukemic cells. 5, 6 This is especially relevant during cytotoxic chemotherapy when massive cell lysis releases proteolytic enzymes. These proteases produce early X-like fibrinogen degradation products that differ from plasmin-generated fragments 5. This proteolytic activity is neither inhibited by epsilon-aminocaproic acid (EACA) nor by aprotinin (Trasylol), distinguishing it from plasmin-mediated degradation 6.
Subtype-Specific Considerations
Acute Promyelocytic Leukemia (APL)
APL represents the most severe coagulopathy among acute leukemias 1. The complex coagulopathy reflects consumptive coagulation combined with both primary and secondary fibrinolysis 1. Hypofibrinogenemia in APL results from depletion of fibrinogen through DIC and secondary hyperfibrinolysis, not from primary hyperfibrinolysis 3.
Non-M3 AML Subtypes
Hypofibrinogenemia occurs in approximately 5% of non-M3 AML cases, most commonly in M5 (monocytic) subtype at 12.1% 7. These patients show significantly elevated markers of both coagulation activation (TAT, F1.2, FPA) and fibrinolysis (D-dimer, FDP), confirming DIC/hyperfibrinolysis as the underlying mechanism 7.
Clinical Implications
The lifespan of transfused fibrinogen is very short in patients with vigorous coagulation activation and fibrinolysis 2, explaining why aggressive replacement therapy is necessary. Fibrinogen levels ≤1.6 g/L independently predict moderate/severe bleeding (p = 0.036) and worse 1-year overall survival in APL 8.
Important Caveat
Platelet count may appear normal despite profound DIC if the baseline was markedly elevated. 2 A 30% or greater drop in platelet count should be considered diagnostic of subclinical DIC even when absolute values remain in the normal range 2. This same principle applies to fibrinogen—a decreasing trend is more significant than absolute values.
Treatment-Related Factors
Chemotherapy-induced tumor lysis exacerbates hypofibrinogenemia through massive release of procoagulant and proteolytic substances 5, 6. However, with appropriate induction therapy, fibrinogen normalizes rapidly (median 5 days in non-M3 AML) 7.
Notably, there is no evidence supporting primary hyperfibrinolysis or unspecific proteolysis as the primary cause of hypofibrinogenemia 3—these are secondary phenomena driven by consumptive coagulopathy.